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Systemic lupus erythematosus (SLE) is a multisystemic inﬂammatory autoimmune disorder. Thrombotic events
occur at a higher incidence among SLE patients. The investigation of thrombin generation (TG) with calibrated
automated thrombogram (CAT) test as a global hemostasis assay is applicable for the overall functional assessment of
the hemostasis. The aim of this study was to characterize the hemostatic alterations observed in SLE by CAT assay. In
this study, CAT parameters and basic coagulation parameters of SLE patients (n= 22) and healthy control subjects
(n= 34) were compared. CAT area under the curve (i.e., endogenous thrombin potential) was lower than normal in
SLE (807 vs. 1,159 nM*min, respectively), whereas other CAT parameters (peak, lag time, time to peak, and velocity
index) and the basic coagulation tests were within the normal range. The presence of anti-phospholipid antibodies
and the applied therapy was not associated with hemostasis parameters in SLE. We concluded that the reported high
risk of thrombosis is not related to TG potential.
Keywords: thrombin generation, systemic lupus erythematosus, thrombosis, endogenous thrombin potential,
anti-phospholipid antibodies
Introduction
Systemic lupus erythematosus (SLE) is a multisystemic inﬂammatory autoimmune disorder
that affects dominantly females. Thrombotic events occur with higher incidence and at a
younger age among SLE patients compared with general population (2, 5); moreover,
thrombosis is among the most common causes of death in SLE (4). In addition to the
generally accepted risk factors, other predisposing factors are identiﬁed in SLE patients.
These include the presence of anti-phospholipid (aPL) antibodies, ethnicity, older age,
disease duration, disease activity, hypertension, nephritis, and corticosteroid treatment (3, 9).
Among these factors the presence of aPL antibodies; particularly that of lupus anticoagulant
(LAC) is associated with the highest risk of thrombosis (18, 20). In line with the high risk of
thrombosis, elevated levels of prothrombin fragments were found at SLE patients with aPL
antibodies (8) particularly at LAC-positive patients (7). The increased levels of prothrombin
fragments demonstrate the prothrombotic state of these patients.
Thrombin generation (TG) tests are global hemostasis assays applicable for the overall
functional assessment of the hemostasis (10). TG measurement is carried out by the detection
of thrombin activity during the entire coagulation process provoked by the addition of small
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amount of triggering agent to the sample. The monitored thrombin activity is graphically
represented on the thrombogram and characterized by descriptive parameters of the TG curve
(Fig. 1). Although TG measurements are still not standardized (11), commercially available
tests are already in use to assess thrombotic risk in a number of disorders (16, 21).
Since TG can reliably reﬂect the general thrombotic or bleeding tendency (10), several
studies applied TG assays for the exploration of the effects of different factors on hemostasis
(1, 19) as well as for the investigation of the pathogenesis of the prothrombotic state in
SLE (6, 13, 14, 17, 19, 22). These studies indicate that in the presence of aPL antibodies,
the hypercoagulable state is characterized by activated protein C (aPC) resistance
(6, 13, 14, 19, 22) and they also suggest the involvement of microparticles (17). However,
the results are inconsistent, probably, due to differences in the applied TG assays.
The aim of this study was to characterize the TG proﬁle of SLE patients with calibrated
automated thrombogram assay (CAT assay, a commercially available TG assay) and its
association with clinical characteristics.
Methods
Patients
In total, 22 patients with various clinical characteristics of SLE and 34 non-affected gender-
and age-matched healthy control subjects were included in the study. Exclusion criteria were
oral anticoagulant or heparin therapy. Clinical characteristics of patients are summarized in
Table I. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score was
calculated for all patients at the time of sampling. Patients were treated with chloroquine
(n= 13, 59.1%), methylprednisolone (n= 18, 81.8%) or prednisolone (n= 1, 4.5%), azathi-
oprine (n= 5, 22.7%), cyclophosphamide (n= 4, 18.2%), mycophenolate mofetil (n= 1,
4.5%), epratuzumab (n= 1, 4.5%), and methotrexate (n= 1, 4.5%). Control subjects were
age- and gender-matched healthy blood donors with no history of rheumatic symptoms
recruited from the laboratory staff.
The project was approved by the Ethical Committee of the University of Szeged (ETT-
TUKEB 905/PI/09). Patients and healthy control subjects gave written informed consent to
participate in the study. The study adhered to the tenets of Declaration of Helsinki.
Laboratory measurements
Venous blood samples were taken by venepuncture into Vacutainer® tubes (Becton Dick-
inson, Franklin Lakes, NJ, USA) containing 3.2% sodium citrate. For standard coagulation
Fig. 1. Thrombogram. The graphical
representation of the TG and its descriptive
parameters. ETP: endogenous thrombin potential
(area under the curve); V index: velocity index
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measurements, samples were centrifuged at 2,500 × g for 10 min at room temperature, and to
obtain platelet poor plasma (PPP) for CAT measurements they were further centrifuged at
2,500 × g for 20 min. Samples were stored at −80 °C until measurement (done within 1
month).
Standard coagulation measurements [activated partial thromboplastin time (aPTT),
prothrombin time (PT), thrombin time (TT) and ﬁbrinogen] were performed on Coag
XL-automated coagulometer (Diagon Ltd., Budapest, Hungary) applying reagents from
Diagon.
TG measurements were performed by applying CAT method (Diagnostica Stago,
Gennevilliers, France). Brieﬂy, 80 μl platelet-free plasma was mixed with 20 μl trigger
(PPP-Reagent, Thrombinoscope BV, Maastricht, The Netherlands) in round bottom 96-well
microtiter plates (Immulon 2HB, Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA). The
measurement was started by the addition of 40 μl FluCa-Kit (Thrombinoscope BV), which
contained CaCl2 and ﬂuorogenic thrombin substrate. Plasma samples were calibrated
individually applying Thrombin Calibrator (Thrombinoscope BV). The generation of
thrombin was measured with Fluoroskan Ascent reader (Thermo Fisher Scientiﬁc Inc.) at
390 nm excitation and 460 nm emission wavelengths. TG parameters [endogenous thrombin
potential (ETP), peak, lag time, time to peak, and velocity index] were calculated by
Thrombinoscope Software (Thrombinoscope BV). The measurements were done in
duplicate.
Statistical analysis
Statistical analysis was performed by Minitab® Release 14.1 (Minitab Inc., State College,
PA, USA). Normal distribution of data was examined by Anderson–Darling normality test.
Table I. Clinical characteristics of SLE patients and healthy control subjects. Qualitative data are expressed as
number (%) and quantitative data as mean± standard deviation or median [1st–3rd interquartile], as appropriate
Patient Control
Number 22 34
Age (years) 48.9± 11.2 48.1± 11.4
Duration of SLE (years) 3.5 [0–14.5] –
SLEDAI 6.0 [3.5–8.5] –
CRP (mg/l) 0 [0–5.1] 2.4 [0–4.4]
ESR (mm/h) 22.0 [8.0–40.8] 9.8 [4.0–14.0]
C3 (mg/dl) 90.4± 39.0 n.d.
C4 (mg/dl) 14.2± 6.9 n.d.
aDNA (U/l) 55.5 [11.0–199.3] n.d.
aPL antibody positivity 6 (27.3%) n.d.
aPL: anti-phospholipid antibodies; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SLE: systemic
lupus erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; aDNA: anti-DNA antibody;
n.d.: not determined
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Qualitative data were expressed as number (%) and quantitative data as mean± standard
deviation or median (1st–3rd interquartile), as appropriate. In case of normal distribution
Student’s t-test or in case of non-normal distribution Mann–Whitney U test was applied to
compare coagulation parameters between SLE patients and the control subjects, and between
subgroups of patients. Patients with or without the following factors were compared as
follows: aPL antibody positivity (27.3%), anti-DNA antibody positivity (59.1%), low C3
complement level (59.1%), and low C4 complement level (22.7%). Coagulation parameters
of SLE patients were correlated with age, duration of SLE, SLEDAI, CRP, and ESR.
Correlations were assessed with Pearson’s or Spearman’s rank coefﬁcient, as appropriate. All
tests were two-sided and p values < 0.05 were considered statistically signiﬁcant.
Results
Standard coagulation tests and CAT parameters of 22 SLE patients and those of 34 control
subjects were measured and compared (Table II). SLE patients had signiﬁcantly shorter aPTT
value than the control subjects; however, both values were within the reference range.
Exclusion of patients with aPL antibodies did not affect the difference (p= 0.005). PT, TT,
and ﬁbrinogen values were not signiﬁcantly different.
ETP value of SLE patients was signiﬁcantly lower than that of control subjects, while
other CAT parameters (peak, lag time, time to peak, and velocity index) were comparable.
After the exclusion of patients with aPL antibodies, the difference between the ETP value of
patients and control subjects remained signiﬁcant (p< 0.0005), whereas other CAT para-
meters were not signiﬁcantly different.
Comparison of SLE patient subgroups showed difference in the PT value of patients
with and without aPL antibodies (INR 1.10 vs. INR 1.02, respectively, p= 0.0480). Both
Table II. Comparison of standard coagulation tests and CAT parameters between SLE patients and control subjects.
Data with normal distribution are expressed as mean± standard deviation and in case of non-normal distribution as
median (1st–3rd interquartile)
Patient Control p
PT (INR) 1.04± 0.09 1.01± 0.08 n.s.
aPTT (s) 32.0 [29.5–36.0] 36.2± 3.3 0.0047
TT (s) 19.2± 1.6 18.5 [17.4–19.2] n.s.
Fibrinogen (g/l) 3.04 [2.71–3.28] 2.88± 0.47 n.s.
ETP (nM*min) 807± 212 1,159± 262 <0.0005
Peak (nM) 174± 64 198 [151–258] n.s.
Lag time (min) 3.03± 0.82 2.30 [2.00–3.30] n.s.
Time to peak (min) 5.77± 1.24 5.94± 1.65 n.s.
Velocity index (nM/min) 61 [38–100] 58 [36–109] n.s.
Signiﬁcant differences are marked with bold letters. aPTT: activated partial thromboplastin time; ETP: endogenous
thrombin potential; INR: international normalized ratio; PT: prothrombin time; TT: thrombin time; n.s.: non-
signiﬁcant
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values were within the normal range, and the difference was clinically irrelevant. No other
difference in hemostasis tests including CAT parameters was observed between SLE patient
subgroups formed in accordance with therapy or disease status.
None of the standard coagulation tests or any CAT parameters of SLE patients were
associated with age, duration of SLE, SLEDAI, and CRP or applied therapy. Fibrinogen
levels and TT values were correlated with ESR (ρ= 0.553, p= 0.008 and ρ= 0.508,
p= 0.016, respectively) within SLE group.
Discussion
Epidemiologic studies have revealed several risk factors that may contribute to the higher risk
of thrombotic events among SLE patients compared with general population. The underlying
mechanism of the elevated thrombotic tendency in SLE is extensively investigated. These
studies imply a complex mechanism characterized by aPC resistance, inhibition of TFPI, and
involvement of microparticles.
TG test as a global hemostasis assay is expectedly an ideal approach for the characteri-
zation of complex hemostatic alterations. In this study, the TG proﬁle of SLE patients was
compared with that of control subjects. Signiﬁcantly decreased ETP value was observed at
SLE patients compared to control subjects, while other CAT parameters did not differ
signiﬁcantly. The basic coagulation test results were within the normal range for SLE patients
and for control group.
Most studies report that for the detection of aPC resistance by TG measurement
exogenous aPC need to be added to the sample (6, 13, 14, 19, 22). However, a decreased
ETP and prolonged lag time have been reportedly observed at LAC-positive patients (12),
even in the absence of exogenous aPC. These results are in line with our ﬁndings of
signiﬁcantly reduced ETP (from 1,159 to 807 nM*min) and a not signiﬁcant still remarkable
(31.7%) prolongation of lag time (from 2.30 to 3.03 min, p= 0.0740) in SLE. Since the aim
of this study was to characterize the TG proﬁle of SLE patients with a commercially available
TG assay (namely CAT), no modiﬁcation was made in the assay protocol provided by the
manufacturer. However, by addition of aPC the CAT assay could have been used to
determine the aPC resistance.
The most important risk factor for thrombosis in SLE is the presence of aPL antibodies.
However, the association between aPL antibodies and TG parameters is controversial
(1, 6, 19, 22), and it is suggested that sensitivity of TG alterations toward aPL antibodies
are strongly affected by preanalytical conditions (15). Moreover, differences in the applied
tests for the determination of aPL antibodies may result in controversial results. In this study,
the effect of different aPL antibodies on coagulation test results was not compared due to the
low number of aPL-positive patients (anti-β2-glycoprotein alone, n= 3; anti-cardiolipin
alone, n= 1; anti-β2-glycoprotein and anti-cardiolipin, n= 2). In this study, no signiﬁcant
difference was observed in the CAT parameters of aPL-positive and aPL-negative SLE
patients, which is in line with the ﬁndings of Boeer et al. (1) who applied a commercially
available TG assay other than us. In these two studies, TG measurements were performed in
accordance with the instructions of the manufacturers, and special preheating of the samples
or addition of aPC were not applied. In this study, one patient with aPL antibodies had
thrombophlebitis, whereas others did not show any thrombotic pattern. Moreover, the ratio of
patients excluded from the study due to oral anticoagulant therapy following a previous
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thrombotic event were comparable between aPL-positive and aPL-negative SLE patients
(3/9= 33% and 5/21= 24%, respectively).
A limitation of the study is that only females were included in this study, however, SLE
may also affect men. It is possible that hemostatic conditions of men differ from those of
women, which should be further investigated.
In conclusion, we performed CAT measurements in SLE patients and found decreased
ETP values. Of note, low ETP values are not consistent with the high thrombotic risk in SLE.
In addition, ETP and other TG characteristics were not related to the presence of aPL
antibodies and the applied therapy in SLE. This indicates that other factors than abnormal TG
capacity contribute to the high thrombotic risk in SLE patients.
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